{"title": "全国新型冠状病毒感染疫情情况", "date": "2023-02-25", "content": "<div class=\"TRS_Editor\"><style type=\"text/css\">\n\n.TRS_Editor P{margin-top:12px;margin-bottom:6px;line-height:2;font-family:宋体;font-size:12pt;}.TRS_Editor DIV{margin-top:12px;margin-bottom:6px;line-height:2;font-family:宋体;font-size:12pt;}.TRS_Editor TD{margin-top:12px;margin-bottom:6px;line-height:2;font-family:宋体;font-size:12pt;}.TRS_Editor TH{margin-top:12px;margin-bottom:6px;line-height:2;font-family:宋体;font-size:12pt;}.TRS_Editor SPAN{margin-top:12px;margin-bottom:6px;line-height:2;font-family:宋体;font-size:12pt;}.TRS_Editor FONT{margin-top:12px;margin-bottom:6px;line-height:2;font-family:宋体;font-size:12pt;}.TRS_Editor UL{margin-top:12px;margin-bottom:6px;line-height:2;font-family:宋体;font-size:12pt;}.TRS_Editor LI{margin-top:12px;margin-bottom:6px;line-height:2;font-family:宋体;font-size:12pt;}.TRS_Editor A{margin-top:12px;margin-bottom:6px;line-height:2;font-family:宋体;font-size:12pt;}</style>\n<div>\n<div>\n<p align=\"justify\">　　<b>一、感染监测数据</b> </p>\n<p align=\"justify\">　　<b><span>（一）全国报告人群新冠病毒核酸检测结果。</span></b><span lang=\"EN-US\"><o:p></o:p></span> </p>\n<p align=\"justify\">　　<span lang=\"EN-US\">2022</span><span>年</span><span lang=\"EN-US\">12</span><span>月</span><span lang=\"EN-US\">9</span><span>日以来，各省份报告人群新冠病毒核酸检测阳性数及阳性率呈现先增加后降低趋势，阳性人数</span><span lang=\"EN-US\">12</span><span>月</span><span lang=\"EN-US\">22</span><span>日达到高峰（</span><span lang=\"EN-US\">694</span><span>万）后波动下降，</span><span lang=\"EN-US\">2</span><span>月</span><span lang=\"EN-US\">23</span><span>日降至</span><span lang=\"EN-US\">12738</span><span>；检测阳性率</span><span lang=\"EN-US\">12</span><span>月</span><span lang=\"EN-US\">25</span><span>日达高峰（</span><span lang=\"EN-US\">29.2%</span><span>）后波动下降，</span><span lang=\"EN-US\">2</span><span>月</span><span lang=\"EN-US\">23</span><span>日为</span><span lang=\"EN-US\">1.4%</span><span>（图</span><span lang=\"EN-US\">1-1</span><span>）。</span><span lang=\"EN-US\"><o:p></o:p></span> </p>\n<p align=\"justify\" style=\"text-align: center;\">　　<img alt=\"\" oldsrc=\"W020230225507750427769.jpg\" src=\"https://www.chinacdc.cn/jkzt/crb/zl/szkb_11803/jszl_13141/202302/W020230225507750427769.jpg\" width=\"740\"/> </p>\n<p align=\"justify\" style=\"text-align: center;\">　　<span lang=\"EN-US\">图<span lang=\"EN-US\">1-1 </span>全国报告人群新型冠状病毒核酸检测阳性数及阳性率变化趋势<span lang=\"EN-US\"><o:p></o:p></span> </span> </p>\n<p align=\"justify\" style=\"text-align: center;\">　　<span>（数据来源于<span lang=\"EN-US\">31</span>个省（区、市）及新疆生产建设兵团报告）<span lang=\"EN-US\"><o:p></o:p></span></span> </p>\n<p align=\"justify\">　　<b><span>（二）全国报告人群新冠病毒抗原检测结果。</span></b><span>各省份报告新冠病毒抗原检测量呈现波动减少趋势，从<span lang=\"EN-US\">2022</span>年<span lang=\"EN-US\">12</span>月<span lang=\"EN-US\">19</span>日的最高<span lang=\"EN-US\">189</span>万波动下降到<span lang=\"EN-US\">2</span>月<span lang=\"EN-US\">23</span>日的<span lang=\"EN-US\">6.8</span>万。新冠病毒抗原检测阳性数及阳性率自<span lang=\"EN-US\">2022</span>年<span lang=\"EN-US\">12</span>月<span lang=\"EN-US\">9</span>日快速上升，<span lang=\"EN-US\">12</span>月<span lang=\"EN-US\">22</span>日达高峰（<span lang=\"EN-US\">33.7</span>万、<span lang=\"EN-US\">21.3%</span>）后波动下降，<span lang=\"EN-US\">2</span>月<span lang=\"EN-US\">23</span>日阳性数降至<span lang=\"EN-US\">337</span>（阳性率为<span lang=\"EN-US\">0.5%</span>）（图<span lang=\"EN-US\">1-2</span>）</span><span>。<span lang=\"EN-US\"><o:p></o:p></span></span> </p>\n<p align=\"justify\" style=\"text-align: center;\">　　<img alt=\"\" oldsrc=\"W020230225502140826234.jpg\" src=\"https://www.chinacdc.cn/jkzt/crb/zl/szkb_11803/jszl_13141/202302/W020230225502140826234.jpg\" width=\"740\"/> </p>\n<p align=\"justify\" style=\"text-align: center;\">　　<span>图<span lang=\"EN-US\">1-2 </span>全国报告人群新型冠状病毒抗原检测阳性数及阳性率变化趋势<span lang=\"EN-US\"><o:p></o:p></span></span> <span lang=\"EN-US\">  <o:p></o:p></span> </p>\n<p align=\"justify\" style=\"text-align: center;\">　　<span>（数据来源于<span lang=\"EN-US\">31</span>个省（区、市）及新疆生产建设兵团报告）<span lang=\"EN-US\"><o:p></o:p></span></span> </p>\n<p align=\"justify\">　　<b>二、全国发热门诊（诊室）诊疗情况</b> </p>\n<p align=\"justify\">　　<b><span>（一）总体就诊人数结果</span></b><span>。</span><span>全国（不含港澳台）发热门诊（诊室）就诊人数于<span lang=\"EN-US\">2022</span>年<span lang=\"EN-US\">12</span>月<span lang=\"EN-US\">23</span>日达到峰值<span lang=\"EN-US\">286.7</span>万人次，随后连续下降；<span lang=\"EN-US\">2023</span>年<span lang=\"EN-US\">1</span>月<span lang=\"EN-US\">23</span>日后就诊人数呈现低位波动，<span lang=\"EN-US\">2</span>月<span lang=\"EN-US\">23</span>日为<span lang=\"EN-US\">14.7</span>万人次<span lang=\"EN-US\">,</span>较峰值下降了<span lang=\"EN-US\">94.9%</span>（图<span lang=\"EN-US\">2-1</span>）。<span lang=\"EN-US\"><o:p></o:p></span></span> </p>\n<p align=\"justify\" style=\"text-align: center;\">　　<img alt=\"\" oldsrc=\"W020230225502140830261.jpg\" src=\"https://www.chinacdc.cn/jkzt/crb/zl/szkb_11803/jszl_13141/202302/W020230225502140830261.jpg\" width=\"740\"/> </p>\n<p align=\"justify\" style=\"text-align: center;\">　　<span>图<span lang=\"EN-US\">2-1  </span>全国发热门诊（诊室）诊疗人数变化趋势<span lang=\"EN-US\"><o:p></o:p></span></span> </p>\n<p align=\"justify\" style=\"text-align: center;\">　　<span>（数据来源于<span lang=\"EN-US\">31</span>个省（区、市）及新疆生产建设兵团报告）<span lang=\"EN-US\"><o:p></o:p></span></span> </p>\n<p align=\"justify\">　　<span>说明：自<span lang=\"EN-US\">2022</span>年<span lang=\"EN-US\">12</span>月<span lang=\"EN-US\">9</span>日起，监测二级以上医疗机构发热门诊诊疗量；<span lang=\"EN-US\">12</span>月<span lang=\"EN-US\">21</span>日起，增加监测社区卫生服务中心和乡镇卫生院发热诊室诊疗量（不含村卫生室和社区卫生服务站）。<span lang=\"EN-US\"><o:p></o:p></span></span> </p>\n<p align=\"justify\">　　<b><span>（二）农村发热门诊（诊室）就诊人数结果。</span></b><span>全国乡镇卫生院发热诊室就诊人数于<span lang=\"EN-US\">2022</span>年<span lang=\"EN-US\">12</span>月<span lang=\"EN-US\">23</span>日达到峰值<span lang=\"EN-US\">92.2</span>万人次，随后波动下降；<span lang=\"EN-US\">2023</span>年<span lang=\"EN-US\">1</span>月<span lang=\"EN-US\">23</span>日后呈现低位波动，<span lang=\"EN-US\">2023</span>年<span lang=\"EN-US\">2</span>月<span lang=\"EN-US\">23</span>日为<span lang=\"EN-US\">3.3</span>万人次，较峰值下降了<span lang=\"EN-US\">96.4%</span>（图<span lang=\"EN-US\">2-2</span>）。<span lang=\"EN-US\"><o:p></o:p></span></span> </p>\n<p align=\"justify\" style=\"text-align: center;\">　　<img alt=\"\" oldsrc=\"W020230225502140839309.jpg\" src=\"https://www.chinacdc.cn/jkzt/crb/zl/szkb_11803/jszl_13141/202302/W020230225502140839309.jpg\" width=\"740\"/> </p>\n<p align=\"justify\" style=\"text-align: center;\">　　<span>图<span lang=\"EN-US\">2-2  </span>全国农村地区乡镇卫生院发热门诊（诊室）就诊人数变化趋势<span lang=\"EN-US\"><o:p></o:p></span></span> </p>\n<p align=\"justify\" style=\"text-align: center;\">　　<span>（数据来源于<span lang=\"EN-US\">31</span>个省（区、市）及新疆生产建设兵团报告）<span lang=\"EN-US\"><o:p></o:p></span></span> </p>\n<p align=\"justify\">　　<span>说明：农村发热患者诊疗量为乡镇卫生院发热诊室诊疗量（不含村卫生室）<span lang=\"EN-US\"><o:p></o:p></span></span> </p>\n<p align=\"justify\">　　<b><span>（三）城市发热门诊就诊人数结果。</span></b><span>全国二级以上医疗机构和城市社区卫生服务中心发热门诊（诊室）就诊人数于<span lang=\"EN-US\">2022</span>年<span lang=\"EN-US\">12</span>月<span lang=\"EN-US\">22</span>日达到峰值<span lang=\"EN-US\">195.4</span>万人次，随后连续下降；<span lang=\"EN-US\">1</span>月<span lang=\"EN-US\">23</span>日后呈低位波动，<span lang=\"EN-US\">2</span>月<span lang=\"EN-US\">23</span>日为<span lang=\"EN-US\">11.5</span>万人次，较峰值下降了<span lang=\"EN-US\">94.1%</span>（图<span lang=\"EN-US\">2-3</span>）。</span><span lang=\"EN-US\"><o:p></o:p></span> </p>\n<p align=\"justify\" style=\"text-align: center;\">　　<img alt=\"\" oldsrc=\"W020230225502140843771.jpg\" src=\"https://www.chinacdc.cn/jkzt/crb/zl/szkb_11803/jszl_13141/202302/W020230225502140843771.jpg\" width=\"740\"/> </p>\n<p align=\"justify\" style=\"text-align: center;\">　　<span>图<span lang=\"EN-US\">2-3  </span>全国城市发热门诊（诊室）就诊人数变化趋势<span lang=\"EN-US\"><o:p></o:p></span></span> </p>\n<p align=\"justify\" style=\"text-align: center;\">　　<span>（数据来源于<span lang=\"EN-US\">31</span>个省（区、市）及新疆生产建设兵团报告）<span lang=\"EN-US\"><o:p></o:p></span></span> </p>\n<p align=\"justify\">　　<span>说明：城市发热门诊诊疗量含二级以上医疗机构和社区卫生服务中心（不含社区卫生服务站）。<span lang=\"EN-US\"><o:p></o:p></span></span> </p>\n<p align=\"justify\">　　<b><span>（四）哨点医院监测结果。</span></b><span lang=\"EN-US\">2022</span><span>年<span lang=\"EN-US\">9</span>月<span lang=\"EN-US\">-12</span>月上旬，全国流感哨点医院每周流感样病例（体温≥<span lang=\"EN-US\">38</span>℃，伴咳嗽或咽痛之一）数量稳定在<span lang=\"EN-US\">10</span>万左右，流感样病例占门（急）诊就诊人数比值在<span lang=\"EN-US\">2.7%-3.6%</span>区间波动。第<span lang=\"EN-US\">50</span>周（<span lang=\"EN-US\">12</span>月<span lang=\"EN-US\">12</span>日<span lang=\"EN-US\">-18</span>日）明显上升至<span lang=\"EN-US\">8.5%</span>，第<span lang=\"EN-US\">51</span>周达到最高<span lang=\"EN-US\">12.1%</span>，第<span lang=\"EN-US\">52</span>周起快速下降。<span lang=\"EN-US\">2023</span>年第<span lang=\"EN-US\">7</span>周（<span lang=\"EN-US\">2</span>月<span lang=\"EN-US\">13</span>日<span lang=\"EN-US\">-19</span>日）流感样病例占比为<span lang=\"EN-US\">1.8%</span>（图<span lang=\"EN-US\">2-4</span>）。<span lang=\"EN-US\"><o:p></o:p></span></span> </p>\n<p align=\"justify\" style=\"text-align: center;\">　　<img alt=\"\" oldsrc=\"W020230225502140843683.jpg\" src=\"https://www.chinacdc.cn/jkzt/crb/zl/szkb_11803/jszl_13141/202302/W020230225502140843683.jpg\" width=\"740\"/> </p>\n<p align=\"justify\" style=\"text-align: center;\">　　<span lang=\"ZH\">图</span><span lang=\"EN-US\">2-4</span><span lang=\"EN-US\"> </span><span>全国</span><span lang=\"ZH\">哨点医院</span><span>报告的</span><span lang=\"ZH\">流感样病例数及占比变化趋势</span><span lang=\"EN-US\"><o:p></o:p></span> </p>\n<p align=\"justify\" style=\"text-align: center;\">　　<span>（数据来源于<span lang=\"EN-US\">824</span>家哨点医院）<span lang=\"EN-US\"><o:p></o:p></span></span> </p>\n<p align=\"justify\">　　<span lang=\"EN-US\">2022</span><span>年第<span lang=\"EN-US\">49</span>周（<span lang=\"EN-US\">12</span>月<span lang=\"EN-US\">9</span>日），流感样病例新冠病毒阳性率开始逐渐增加，在第<span lang=\"EN-US\">51</span>和<span lang=\"EN-US\">52</span>周期间达峰值后持续下降，<span lang=\"EN-US\">2023</span>年第<span lang=\"EN-US\">7</span>周（<span lang=\"EN-US\">2</span>月<span lang=\"EN-US\">13-19</span>日）新冠病毒阳性率已下降至<span lang=\"EN-US\">3.4%</span>。<span lang=\"EN-US\">2022</span>年第<span lang=\"EN-US\">49</span>周以来，流感病毒阳性率则逐步降低，<span lang=\"EN-US\">12</span>月下旬至<span lang=\"EN-US\">2</span>月初处于极低水平（低于<span lang=\"EN-US\">1.0%</span>）；<span lang=\"EN-US\">2023</span>年第<span lang=\"EN-US\">7</span>周，流感病毒阳性率增加至<span lang=\"EN-US\">14.3%</span>（图<span lang=\"EN-US\">2-5</span>）。<span lang=\"EN-US\"><o:p></o:p></span></span> </p>\n<p align=\"justify\" style=\"text-align: center;\">　　<img alt=\"\" oldsrc=\"W020230225502140843962.jpg\" src=\"https://www.chinacdc.cn/jkzt/crb/zl/szkb_11803/jszl_13141/202302/W020230225502140843962.jpg\" width=\"740\"/> </p>\n<p align=\"justify\" style=\"text-align: center;\">　　<span lang=\"ZH\">图</span><span lang=\"EN-US\">2-5 </span><span>全国</span><span lang=\"ZH\">哨点医院流感样病例新冠和流感病毒阳性率变化趋势</span><span lang=\"EN-US\"><o:p></o:p></span> </p>\n<p align=\"justify\" style=\"text-align: center;\">　　<span>（数据来源于<span lang=\"EN-US\">402</span>家网络实验室）<span lang=\"EN-US\"><o:p></o:p></span></span> </p>\n<p align=\"justify\">　　<b>三、住院诊疗情况</b> </p>\n<p align=\"justify\">　　<b><span>（一）在院新冠病毒感染者结果。</span></b><span>全国在院新冠病毒感染者于<span lang=\"EN-US\">2023</span>年<span lang=\"EN-US\">1</span>月<span lang=\"EN-US\">5</span>日达到峰值<span lang=\"EN-US\">162.5</span>万人，随后持续下降；<span lang=\"EN-US\">2</span>月<span lang=\"EN-US\">23</span>日下降至<span lang=\"EN-US\">1.45</span>万人，较峰值减少了<span lang=\"EN-US\">99.1%</span>（图<span lang=\"EN-US\">3-1</span>）。<span lang=\"EN-US\"><o:p></o:p></span></span> </p>\n<p align=\"justify\" style=\"text-align: center;\">　　<img alt=\"\" oldsrc=\"W020230225502140858352.jpg\" src=\"https://www.chinacdc.cn/jkzt/crb/zl/szkb_11803/jszl_13141/202302/W020230225502140858352.jpg\" width=\"740\"/> </p>\n<p align=\"justify\" style=\"text-align: center;\">　　<span>图<span lang=\"EN-US\">3-1  </span>全国在院新冠病毒感染者每日变化情况<span lang=\"EN-US\"><o:p></o:p></span></span> </p>\n<p align=\"justify\" style=\"text-align: center;\">　　<span>（数据来源于<span lang=\"EN-US\">31</span>个省（区、市）及新疆生产建设兵团报告）<span lang=\"EN-US\"><o:p></o:p></span></span> </p>\n<p align=\"justify\">　　<b><span>（二）在院新冠病毒感染阳性重症患者结果。</span></b><span>全国在院新冠病毒感染者中，重症患者数量于<span lang=\"EN-US\">2022</span>年<span lang=\"EN-US\">12</span>月<span lang=\"EN-US\">27</span>日至<span lang=\"EN-US\">2023</span>年<span lang=\"EN-US\">1</span>月<span lang=\"EN-US\">3</span>日期间每日增量近<span lang=\"EN-US\">1</span>万，<span lang=\"EN-US\">1</span>月<span lang=\"EN-US\">4</span>日增量明显下降，<span lang=\"EN-US\">1</span>月<span lang=\"EN-US\">5</span>日达到峰值<span lang=\"EN-US\">12.8</span>万后持续下降，<span lang=\"EN-US\">2</span>月<span lang=\"EN-US\">23</span>日下降至<span lang=\"EN-US\">8</span>例（其中新冠病毒感染重症<span lang=\"EN-US\">0</span>例、基础性疾病重症合并新冠病毒感染<span lang=\"EN-US\">8</span>例），较峰值下降了<span lang=\"EN-US\">99.9%</span>（图<span lang=\"EN-US\">3-2</span>）。<span lang=\"EN-US\"><o:p></o:p></span></span> </p>\n<p align=\"justify\" style=\"text-align: center;\">　　<img alt=\"\" oldsrc=\"W020230225502140850273.jpg\" src=\"https://www.chinacdc.cn/jkzt/crb/zl/szkb_11803/jszl_13141/202302/W020230225502140850273.jpg\" width=\"740\"/> </p>\n<p align=\"justify\" style=\"text-align: center;\">　　<span>图<span lang=\"EN-US\">3-2  </span>全国在院新冠病毒感染阳性重症患者变化情况<span lang=\"EN-US\"><o:p></o:p></span></span> </p>\n<p align=\"justify\" style=\"text-align: center;\">　　<span>（数据来源于<span lang=\"EN-US\">31</span>个省（区、市）及新疆生产建设兵团报告）<span lang=\"EN-US\"><o:p></o:p></span></span> </p>\n<p align=\"justify\">　　<b><span>（三）在院新冠病毒感染死亡情况。</span></b><span>在院新冠病毒感染死亡病例数于<span lang=\"EN-US\">1</span>月<span lang=\"EN-US\">4</span>日达到每日峰值<span lang=\"EN-US\">4273</span>例，随后持续下降，<span lang=\"EN-US\">2</span>月<span lang=\"EN-US\">23</span>日下降至<span lang=\"EN-US\">0</span>例（图<span lang=\"EN-US\">3-3</span>）。<span lang=\"EN-US\">2</span>月<span lang=\"EN-US\">17</span>日至<span lang=\"EN-US\">2</span>月<span lang=\"EN-US\">23</span>日，<span lang=\"EN-US\">31</span>个省（自治区、直辖市）及新疆生产建设兵团医疗机构累计在院新冠病毒感染相关死亡病例<span lang=\"EN-US\">7</span>例，其中新冠病毒感染导致呼吸衰竭死亡<span lang=\"EN-US\">0</span>例、基础疾病合并新冠病毒感染死亡<span lang=\"EN-US\">7</span>例。<span lang=\"EN-US\"><o:p></o:p></span></span> </p>\n<p align=\"justify\" style=\"text-align: center;\">　　<img alt=\"\" oldsrc=\"W020230225502140863529.jpg\" src=\"https://www.chinacdc.cn/jkzt/crb/zl/szkb_11803/jszl_13141/202302/W020230225502140863529.jpg\" width=\"740\"/> </p>\n<p align=\"justify\" style=\"text-align: center;\">　　<span>图<span lang=\"EN-US\">3-3  </span>全国在院新冠病毒感染死亡病例变化情况<span lang=\"EN-US\"><o:p></o:p></span></span> <span lang=\"EN-US\"> </span> </p>\n<p align=\"justify\" style=\"text-align: center;\">　　<span>（数据来源于<span lang=\"EN-US\">31</span>个省（区、市）及新疆生产建设兵团报告）<span lang=\"EN-US\"><o:p></o:p></span></span> </p>\n<p align=\"justify\">　　<b>四、新冠病毒感染本土病例病毒变异监测情况</b> </p>\n<p align=\"justify\">　　<b><span>（一）总体情况。</span></b><span lang=\"EN-US\">2022</span><span>年<span lang=\"EN-US\">9</span>月<span lang=\"EN-US\">26</span>日至<span lang=\"EN-US\">2023</span>年<span lang=\"EN-US\">2</span>月<span lang=\"EN-US\">23</span>日，全国共报送<span lang=\"EN-US\">27315</span>例本土病例新冠病毒基因组有效序列，均为奥密克戎变异株，共存在<span lang=\"EN-US\">80</span>个进化分支，主要流行株为<span lang=\"EN-US\">BA.5.2.48</span>（<span lang=\"EN-US\">53.9%</span>）、<span lang=\"EN-US\">BF.7.14</span>（<span lang=\"EN-US\">25.2%</span>）和<span lang=\"EN-US\">BA.5.2.49</span>（<span lang=\"EN-US\">13.4%</span>）。<span lang=\"EN-US\">BA.5.2</span>等<span lang=\"EN-US\">18</span>种进化分支构成比在<span lang=\"EN-US\">0.1%-2.4%</span>之间，<span lang=\"EN-US\">59</span>个进化分支的构成比小于<span lang=\"EN-US\">0.1%</span>（共占<span lang=\"EN-US\">0.7%</span>）（图<span lang=\"EN-US\">4-1</span>）。<span lang=\"EN-US\"><o:p></o:p></span></span> </p>\n<p align=\"justify\" style=\"text-align: center;\">　　<img alt=\"\" oldsrc=\"W020230225502140868365.jpg\" src=\"https://www.chinacdc.cn/jkzt/crb/zl/szkb_11803/jszl_13141/202302/W020230225502140868365.jpg\" width=\"740\"/> </p>\n<p align=\"justify\" style=\"text-align: center;\">　　<span>图<span lang=\"EN-US\">4-1 </span>全国新型冠状病毒变异株变化趋势图<span lang=\"EN-US\"><o:p></o:p></span></span> </p>\n<p align=\"justify\">　　<span>说明：<span lang=\"EN-US\">1.</span>采样日期：<span lang=\"EN-US\">2022</span>年<span lang=\"EN-US\">9</span>月<span lang=\"EN-US\">26</span>日至<span lang=\"EN-US\">2023</span>年<span lang=\"EN-US\">2</span>月<span lang=\"EN-US\">21</span>日。<span lang=\"EN-US\"><o:p></o:p></span></span> </p>\n<p align=\"justify\">　　<span lang=\"EN-US\">2.</span><span>图中标记的数字分别为<span lang=\"EN-US\">BA.5.2.48</span>、<span lang=\"EN-US\">BF.7.14</span>和<span lang=\"EN-US\">BA.5.2.49</span>进化分支有效基因组序列数量。<span lang=\"EN-US\"><o:p></o:p></span></span> </p>\n<p align=\"justify\">　　<span lang=\"EN-US\">3.“</span><span>其它<span lang=\"EN-US\">”</span>指全国范围<span lang=\"EN-US\">Omicron</span>变异株构成比小于<span lang=\"EN-US\">0.1%</span>的进化分支。<span lang=\"EN-US\"><o:p></o:p></span></span> </p>\n<p align=\"justify\">　　<b><span>（二）<span lang=\"EN-US\">12</span>月以来本土病例病毒变异株监测情况。</span></b><span lang=\"EN-US\">2022</span><span>年<span lang=\"EN-US\">12</span>月<span lang=\"EN-US\">1</span>日至<span lang=\"EN-US\">2023</span>年<span lang=\"EN-US\">2</span>月<span lang=\"EN-US\">23</span>日，全国共报送<span lang=\"EN-US\">18618</span>例本土病例新冠病毒基因组有效序列，全部为奥密克戎变异株，共存在<span lang=\"EN-US\">36</span>个进化分支。主要流行株为<span lang=\"EN-US\">BA.5.2.48</span>（<span lang=\"EN-US\">60.5%</span>）和<span lang=\"EN-US\">BF.7.14</span>（<span lang=\"EN-US\">28.9%</span>）（表<span lang=\"EN-US\">4-1</span>）。共发现本土重点关注变异株<span lang=\"EN-US\">22</span>例，其中，<span lang=\"EN-US\">1</span>例<span lang=\"EN-US\">XBB.1</span>，<span lang=\"EN-US\">5</span>例<span lang=\"EN-US\">XBB.1.5</span>，<span lang=\"EN-US\">4</span>例<span lang=\"EN-US\">BQ.1</span>，<span lang=\"EN-US\">5</span>例<span lang=\"EN-US\">BQ.1.1</span>，<span lang=\"EN-US\">1</span>例<span lang=\"EN-US\">BQ.1.1.17</span>，<span lang=\"EN-US\">4</span>例<span lang=\"EN-US\">BQ.1.2</span>和<span lang=\"EN-US\">2</span>例<span lang=\"EN-US\">BQ.1.8</span>。<span lang=\"EN-US\"><o:p></o:p></span></span> </p>\n<p align=\"justify\" style=\"text-align: center;\">　　<b><span>表<span lang=\"EN-US\">4-1 </span>全国新冠病毒变异株情况<span lang=\"EN-US\"><o:p></o:p></span></span></b> </p>\n<p align=\"justify\" style=\"text-align: center;\">　　<span>（<span lang=\"EN-US\">2022</span>年<span lang=\"EN-US\">12</span>月<span lang=\"EN-US\">1</span>日至<span lang=\"EN-US\">2023</span>年<span lang=\"EN-US\">2</span>月<span lang=\"EN-US\">23</span>日）<span lang=\"EN-US\"><o:p></o:p></span></span> <span> </span></p>\n<div align=\"center\">\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoTableGrid\" style=\"border-collapse:collapse;border:none;mso-border-alt:solid windowtext .5pt;\n mso-yfti-tbllook:1184;mso-padding-alt:0cm 5.4pt 0cm 5.4pt\">\n<thead>\n<tr style=\"mso-yfti-irow:0;mso-yfti-firstrow:yes;height:22.7pt;mso-height-rule:\n   exactly\">\n<td style=\"width:158.15pt;border:solid windowtext 1.0pt;\n   mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:\n   22.7pt;mso-height-rule:exactly\" width=\"211\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-indent:0cm;\n   mso-char-indent-count:0;mso-pagination:widow-orphan;vertical-align:middle\"><span style=\"font-size:15.0pt;font-family:仿宋;mso-font-kerning:0pt;mso-bidi-font-weight:\n   bold\">奥密克戎</span><span style=\"font-size: 15pt; font-family: 仿宋;\">进化分支</span><span lang=\"EN-US\" style=\"font-size:15.0pt;font-family:仿宋;mso-font-kerning:0pt\"><o:p></o:p></span></p>\n</td>\n<td style=\"width:172.75pt;border:solid windowtext 1.0pt;\n   border-left:none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:\n   solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:22.7pt;mso-height-rule:\n   exactly\" width=\"230\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-indent:30.0pt;\n   line-height:115%\"><span style=\"font-size: 15pt; line-height: 115%; font-family: 仿宋;\">构成比（<span lang=\"EN-US\">%</span>）</span><span lang=\"EN-US\" style=\"font-size:15.0pt;\n   line-height:115%;font-family:仿宋;mso-font-kerning:0pt\"><o:p></o:p></span></p>\n</td>\n</tr>\n</thead>\n<tbody>\n<tr style=\"mso-yfti-irow:1;height:22.7pt;mso-height-rule:exactly\">\n<td style=\"width:158.15pt;border:solid windowtext 1.0pt;border-top:\n  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;\n  padding:0cm 5.4pt 0cm 5.4pt;height:22.7pt;mso-height-rule:exactly\" width=\"211\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-indent:30.0pt;\n  line-height:115%;mso-pagination:widow-orphan\"><span lang=\"EN-US\" style=\"font-size: 15pt; line-height: 115%; font-family: 仿宋;\">BA.5.2.48</span><span lang=\"EN-US\" style=\"font-size: 15pt; line-height: 115%; font-family: 仿宋;\"><o:p></o:p></span></p>\n</td>\n<td style=\"width:172.75pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;\n  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:22.7pt;\n  mso-height-rule:exactly\" width=\"230\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-indent:30.0pt;\n  line-height:115%;mso-pagination:widow-orphan\"><span lang=\"EN-US\" style=\"font-size: 15pt; line-height: 115%; font-family: 仿宋;\">60.5</span><span lang=\"EN-US\" style=\"font-size: 15pt; line-height: 115%; font-family: 仿宋;\"><o:p></o:p></span></p>\n</td>\n</tr>\n<tr style=\"mso-yfti-irow:2;height:22.7pt;mso-height-rule:exactly\">\n<td style=\"width:158.15pt;border:solid windowtext 1.0pt;border-top:\n  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;\n  padding:0cm 5.4pt 0cm 5.4pt;height:22.7pt;mso-height-rule:exactly\" width=\"211\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-indent:30.0pt;\n  line-height:115%;mso-pagination:widow-orphan\"><span lang=\"EN-US\" style=\"font-size: 15pt; line-height: 115%; font-family: 仿宋;\">BF.7.14</span><span lang=\"EN-US\" style=\"font-size: 15pt; line-height: 115%; font-family: 仿宋;\"><o:p></o:p></span></p>\n</td>\n<td style=\"width:172.75pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;\n  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:22.7pt;\n  mso-height-rule:exactly\" width=\"230\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-indent:30.0pt;\n  line-height:115%;mso-pagination:widow-orphan\"><span lang=\"EN-US\" style=\"font-size: 15pt; line-height: 115%; font-family: 仿宋;\">28.9</span><span lang=\"EN-US\" style=\"font-size: 15pt; line-height: 115%; font-family: 仿宋;\"><o:p></o:p></span></p>\n</td>\n</tr>\n<tr style=\"mso-yfti-irow:3;height:22.7pt;mso-height-rule:exactly\">\n<td style=\"width:158.15pt;border:solid windowtext 1.0pt;border-top:\n  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;\n  padding:0cm 5.4pt 0cm 5.4pt;height:22.7pt;mso-height-rule:exactly\" width=\"211\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-indent:30.0pt;\n  line-height:115%;mso-pagination:widow-orphan\"><span lang=\"EN-US\" style=\"font-size: 15pt; line-height: 115%; font-family: 仿宋;\">BA.5.2.49</span><span lang=\"EN-US\" style=\"font-size: 15pt; line-height: 115%; font-family: 仿宋;\"><o:p></o:p></span></p>\n</td>\n<td style=\"width:172.75pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;\n  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:22.7pt;\n  mso-height-rule:exactly\" width=\"230\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-indent:30.0pt;\n  line-height:115%;mso-pagination:widow-orphan\"><span lang=\"EN-US\" style=\"font-size: 15pt; line-height: 115%; font-family: 仿宋;\">6.4</span><span lang=\"EN-US\" style=\"font-size: 15pt; line-height: 115%; font-family: 仿宋;\"><o:p></o:p></span></p>\n</td>\n</tr>\n<tr style=\"mso-yfti-irow:4;height:22.7pt;mso-height-rule:exactly\">\n<td style=\"width:158.15pt;border:solid windowtext 1.0pt;border-top:\n  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;\n  padding:0cm 5.4pt 0cm 5.4pt;height:22.7pt;mso-height-rule:exactly\" width=\"211\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-indent:30.0pt;\n  line-height:115%;mso-pagination:widow-orphan\"><span lang=\"EN-US\" style=\"font-size: 15pt; line-height: 115%; font-family: 仿宋;\">BA.5.2</span><span lang=\"EN-US\" style=\"font-size: 15pt; line-height: 115%; font-family: 仿宋;\"><o:p></o:p></span></p>\n</td>\n<td style=\"width:172.75pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;\n  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:22.7pt;\n  mso-height-rule:exactly\" width=\"230\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-indent:30.0pt;\n  line-height:115%;mso-pagination:widow-orphan\"><span lang=\"EN-US\" style=\"font-size: 15pt; line-height: 115%; font-family: 仿宋;\">2.1</span><span lang=\"EN-US\" style=\"font-size: 15pt; line-height: 115%; font-family: 仿宋;\"><o:p></o:p></span></p>\n</td>\n</tr>\n<tr style=\"mso-yfti-irow:5;height:22.7pt;mso-height-rule:exactly\">\n<td style=\"width:158.15pt;border:solid windowtext 1.0pt;border-top:\n  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;\n  padding:0cm 5.4pt 0cm 5.4pt;height:22.7pt;mso-height-rule:exactly\" width=\"211\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-indent:30.0pt;\n  line-height:115%;mso-pagination:widow-orphan\"><span lang=\"EN-US\" style=\"font-size: 15pt; line-height: 115%; font-family: 仿宋;\">BF.7</span><span lang=\"EN-US\" style=\"font-size: 15pt; line-height: 115%; font-family: 仿宋;\"><o:p></o:p></span></p>\n</td>\n<td style=\"width:172.75pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;\n  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:22.7pt;\n  mso-height-rule:exactly\" width=\"230\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-indent:30.0pt;\n  line-height:115%;mso-pagination:widow-orphan\"><span lang=\"EN-US\" style=\"font-size: 15pt; line-height: 115%; font-family: 仿宋;\">1.0</span><span lang=\"EN-US\" style=\"font-size: 15pt; line-height: 115%; font-family: 仿宋;\"><o:p></o:p></span></p>\n</td>\n</tr>\n<tr style=\"mso-yfti-irow:6;height:22.7pt;mso-height-rule:exactly\">\n<td style=\"width:158.15pt;border:solid windowtext 1.0pt;border-top:\n  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;\n  padding:0cm 5.4pt 0cm 5.4pt;height:22.7pt;mso-height-rule:exactly\" width=\"211\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-indent:30.0pt;\n  line-height:115%;mso-pagination:widow-orphan\"><span lang=\"EN-US\" style=\"font-size: 15pt; line-height: 115%; font-family: 仿宋;\">BA.5.1</span><span lang=\"EN-US\" style=\"font-size: 15pt; line-height: 115%; font-family: 仿宋;\"><o:p></o:p></span></p>\n</td>\n<td style=\"width:172.75pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;\n  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:22.7pt;\n  mso-height-rule:exactly\" width=\"230\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-indent:30.0pt;\n  line-height:115%;mso-pagination:widow-orphan\"><span lang=\"EN-US\" style=\"font-size: 15pt; line-height: 115%; font-family: 仿宋;\">0.4</span><span lang=\"EN-US\" style=\"font-size: 15pt; line-height: 115%; font-family: 仿宋;\"><o:p></o:p></span></p>\n</td>\n</tr>\n<tr style=\"mso-yfti-irow:7;height:22.7pt;mso-height-rule:exactly\">\n<td style=\"width:158.15pt;border:solid windowtext 1.0pt;border-top:\n  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;\n  padding:0cm 5.4pt 0cm 5.4pt;height:22.7pt;mso-height-rule:exactly\" width=\"211\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-indent:30.0pt;\n  line-height:115%;mso-pagination:widow-orphan\"><span lang=\"EN-US\" style=\"font-size: 15pt; line-height: 115%; font-family: 仿宋;\">BA.2.76</span><span lang=\"EN-US\" style=\"font-size: 15pt; line-height: 115%; font-family: 仿宋;\"><o:p></o:p></span></p>\n</td>\n<td style=\"width:172.75pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;\n  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:22.7pt;\n  mso-height-rule:exactly\" width=\"230\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-indent:30.0pt;\n  line-height:115%;mso-pagination:widow-orphan\"><span lang=\"EN-US\" style=\"font-size: 15pt; line-height: 115%; font-family: 仿宋;\">0.1</span><span lang=\"EN-US\" style=\"font-size: 15pt; line-height: 115%; font-family: 仿宋;\"><o:p></o:p></span></p>\n</td>\n</tr>\n<tr style=\"mso-yfti-irow:8;height:22.7pt;mso-height-rule:exactly\">\n<td style=\"width:158.15pt;border:solid windowtext 1.0pt;border-top:\n  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;\n  padding:0cm 5.4pt 0cm 5.4pt;height:22.7pt;mso-height-rule:exactly\" width=\"211\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-indent:30.0pt;\n  line-height:115%;mso-pagination:widow-orphan\"><span lang=\"EN-US\" style=\"font-size: 15pt; line-height: 115%; font-family: 仿宋;\">BA.5.2.1</span><span lang=\"EN-US\" style=\"font-size: 15pt; line-height: 115%; font-family: 仿宋;\"><o:p></o:p></span></p>\n</td>\n<td style=\"width:172.75pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;\n  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:22.7pt;\n  mso-height-rule:exactly\" width=\"230\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-indent:30.0pt;\n  line-height:115%;mso-pagination:widow-orphan\"><span lang=\"EN-US\" style=\"font-size: 15pt; line-height: 115%; font-family: 仿宋;\">0.1</span><span lang=\"EN-US\" style=\"font-size: 15pt; line-height: 115%; font-family: 仿宋;\"><o:p></o:p></span></p>\n</td>\n</tr>\n<tr style=\"mso-yfti-irow:9;height:22.7pt;mso-height-rule:exactly\">\n<td style=\"width:158.15pt;border:solid windowtext 1.0pt;border-top:\n  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;\n  padding:0cm 5.4pt 0cm 5.4pt;height:22.7pt;mso-height-rule:exactly\" width=\"211\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-indent:30.0pt;\n  line-height:115%;mso-pagination:widow-orphan\"><span lang=\"EN-US\" style=\"font-size: 15pt; line-height: 115%; font-family: 仿宋;\">BA.5.2.20</span><span lang=\"EN-US\" style=\"font-size: 15pt; line-height: 115%; font-family: 仿宋;\"><o:p></o:p></span></p>\n</td>\n<td style=\"width:172.75pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;\n  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:22.7pt;\n  mso-height-rule:exactly\" width=\"230\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-indent:30.0pt;\n  line-height:115%;mso-pagination:widow-orphan\"><span lang=\"EN-US\" style=\"font-size: 15pt; line-height: 115%; font-family: 仿宋;\">0.1</span><span lang=\"EN-US\" style=\"font-size: 15pt; line-height: 115%; font-family: 仿宋;\"><o:p></o:p></span></p>\n</td>\n</tr>\n<tr style=\"mso-yfti-irow:10;height:22.7pt;mso-height-rule:exactly\">\n<td style=\"width:158.15pt;border:solid windowtext 1.0pt;border-top:\n  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;\n  padding:0cm 5.4pt 0cm 5.4pt;height:22.7pt;mso-height-rule:exactly\" width=\"211\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-indent:30.0pt;\n  line-height:115%;mso-pagination:widow-orphan\"><span lang=\"EN-US\" style=\"font-size: 15pt; line-height: 115%; font-family: 仿宋;\">BN.1.3</span><span lang=\"EN-US\" style=\"font-size: 15pt; line-height: 115%; font-family: 仿宋;\"><o:p></o:p></span></p>\n</td>\n<td style=\"width:172.75pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;\n  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:22.7pt;\n  mso-height-rule:exactly\" width=\"230\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-indent:30.0pt;\n  line-height:115%;mso-pagination:widow-orphan\"><span lang=\"EN-US\" style=\"font-size: 15pt; line-height: 115%; font-family: 仿宋;\">0.1</span><span lang=\"EN-US\" style=\"font-size: 15pt; line-height: 115%; font-family: 仿宋;\"><o:p></o:p></span></p>\n</td>\n</tr>\n<tr style=\"mso-yfti-irow:11;height:22.7pt;mso-height-rule:exactly\">\n<td style=\"width:158.15pt;border:solid windowtext 1.0pt;border-top:\n  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;\n  padding:0cm 5.4pt 0cm 5.4pt;height:22.7pt;mso-height-rule:exactly\" width=\"211\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-indent:30.0pt;\n  line-height:115%\"><span style=\"font-size: 15pt; line-height: 115%; font-family: 仿宋;\">其它<span lang=\"EN-US\"><o:p></o:p></span></span></p>\n</td>\n<td style=\"width:172.75pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;\n  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:22.7pt;\n  mso-height-rule:exactly\" width=\"230\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-indent:30.0pt;\n  line-height:115%\"><span lang=\"EN-US\" style=\"font-size: 15pt; line-height: 115%; font-family: 仿宋;\">0.3<o:p></o:p></span></p>\n</td>\n</tr>\n<tr style=\"mso-yfti-irow:12;mso-yfti-lastrow:yes;height:22.7pt;mso-height-rule:\n  exactly\">\n<td style=\"width:158.15pt;border:solid windowtext 1.0pt;border-top:\n  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;\n  padding:0cm 5.4pt 0cm 5.4pt;height:22.7pt;mso-height-rule:exactly\" width=\"211\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-indent:30.0pt;\n  line-height:115%\"><span style=\"font-size: 15pt; line-height: 115%; font-family: 仿宋;\">合计<span lang=\"EN-US\"><o:p></o:p></span></span></p>\n</td>\n<td style=\"width:172.75pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;\n  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:22.7pt;\n  mso-height-rule:exactly\" width=\"230\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;text-indent:30.0pt;\n  line-height:115%\"><span lang=\"EN-US\" style=\"font-size: 15pt; line-height: 115%; font-family: 仿宋;\">100.0<o:p></o:p></span></p>\n</td>\n</tr>\n</tbody>\n</table>\n</div>\n<p align=\"justify\" style=\"text-align: center;\"> </p>\n<p align=\"justify\">　　<b><span>（三）新冠病毒变异分省份情况。</span></b><span>总体来看，北京、内蒙古和天津以<span lang=\"EN-US\">BF.7</span>及亚分支为优势株；其他省份均以<span lang=\"EN-US\">BA.5.2</span>及亚分支为优势株（图<span lang=\"EN-US\">4-2</span>）。<span lang=\"EN-US\"><o:p></o:p></span></span> </p>\n<p align=\"justify\" style=\"text-align: center;\">　　<img alt=\"\" oldsrc=\"W020230225502140878783.jpg\" src=\"https://www.chinacdc.cn/jkzt/crb/zl/szkb_11803/jszl_13141/202302/W020230225502140878783.jpg\" width=\"740\"/> </p>\n<p align=\"justify\" style=\"text-align: center;\">　　<span>图<span lang=\"EN-US\">4-2  </span>各省份新冠病毒变异监测情况<span lang=\"EN-US\"><o:p></o:p></span></span> </p>\n<p align=\"justify\">　　<span>说明：<span lang=\"EN-US\">1.</span>采样时间：<span lang=\"EN-US\">2022</span>年<span lang=\"EN-US\">12</span>月<span lang=\"EN-US\">1</span>日<span lang=\"EN-US\">-2023</span>年<span lang=\"EN-US\">2</span>月<span lang=\"EN-US\">21</span>日</span><span>；<span lang=\"EN-US\"><o:p></o:p></span></span> </p>\n<p align=\"justify\">　　<span lang=\"EN-US\">2.</span><span>图中标记的数字分别为<span lang=\"EN-US\">BA.5.2.48</span>、<span lang=\"EN-US\">BF.7.14</span>和<span lang=\"EN-US\">BA.5.2.49</span>进化分支有效基因组序列数量。<span lang=\"EN-US\"><o:p></o:p></span></span> </p>\n<p align=\"justify\">　　3.“其它”指全国范围Omicron变异株构成比小于0.1%的进化分支。</p>\n<p align=\"justify\">　　<b>五、新冠病毒疫苗接种进展</b> </p>\n<p align=\"justify\">　　<span>截至<span lang=\"EN-US\">2023</span>年<span lang=\"EN-US\">2</span>月<span lang=\"EN-US\">23</span>日，<span lang=\"EN-US\">31</span>个省（自治区、直辖市）和新疆生产建设兵团累计完成接种新冠病毒疫苗<span lang=\"EN-US\">349232.9</span>万剂次（图<span lang=\"EN-US\">5-1</span>）。接种总人数<span lang=\"EN-US\">131040.6</span>万人，完成全程接种<span lang=\"EN-US\">127692.0</span>万人，完成第一剂次加强免疫接种<span lang=\"EN-US\">82732.2</span>万人。全人群第一剂次、全程接种覆盖比例分别达到<span lang=\"EN-US\">93.0%</span>和<span lang=\"EN-US\">90.6%</span>（图<span lang=\"EN-US\">5-2</span>）。<span lang=\"EN-US\">60</span>岁以上老年人累计报告接种新冠病毒疫苗<span lang=\"EN-US\">67983.5</span>万剂次，接种总人数<span lang=\"EN-US\">24168.8</span>万人，完成全程接种<span lang=\"EN-US\">23030.9</span>万人，完成第一剂次加强免疫接种<span lang=\"EN-US\">19283.2</span>万人。<span lang=\"EN-US\"><o:p></o:p></span></span> </p>\n<p align=\"justify\" style=\"text-align: center;\">　　<img alt=\"\" oldsrc=\"W020230225502140881390.jpg\" src=\"https://www.chinacdc.cn/jkzt/crb/zl/szkb_11803/jszl_13141/202302/W020230225502140881390.jpg\" width=\"740\"/> </p>\n<p align=\"justify\" style=\"text-align: center;\">　　<span>图<span lang=\"EN-US\">5-1  </span>分月新冠病毒疫苗累计接种剂次<span lang=\"EN-US\"><o:p></o:p></span></span> </p>\n<p align=\"justify\" style=\"text-align: center;\">　　<span>（数据来源于<span lang=\"EN-US\">31</span>个省（区、市）及新疆生产建设兵团报告）<span lang=\"EN-US\"><o:p></o:p></span></span> </p>\n<p align=\"justify\" style=\"text-align: center;\">　　<img alt=\"\" oldsrc=\"W020230225502140899799.jpg\" src=\"https://www.chinacdc.cn/jkzt/crb/zl/szkb_11803/jszl_13141/202302/W020230225502140899799.jpg\" width=\"740\"/> </p>\n<p align=\"justify\" style=\"text-align: center;\">　　<span>图<span lang=\"EN-US\">5-2  </span>分月全人群中第一剂次、全程接种覆盖比例<span lang=\"EN-US\"><o:p></o:p></span></span> </p>\n<p align=\"justify\" style=\"text-align: center;\">　　<span>（数据来源于<span lang=\"EN-US\">31</span>个省（区、市）及新疆生产建设兵团报告）<span lang=\"EN-US\"><o:p></o:p></span></span> </p>\n<p align=\"justify\">　　<span>以<span lang=\"EN-US\">2022</span>年底全国老年人专项摸底调查人口数为基数统计，截至<span lang=\"EN-US\">2023</span>年<span lang=\"EN-US\">2</span>月<span lang=\"EN-US\">23</span>日，<span lang=\"EN-US\">60</span>岁以上老年人第一剂次接种覆盖人数占老年人群的<span lang=\"EN-US\">96.1%</span>，全程接种、第一剂次加强免疫接种人数分别占符合接种时间间隔老年人群的<span lang=\"EN-US\">96.6%</span>、<span lang=\"EN-US\">92.4%</span>（图<span lang=\"EN-US\">5-3</span>）。<span lang=\"EN-US\"><o:p></o:p></span></span> </p>\n<p align=\"justify\" style=\"text-align: center;\">　　<img alt=\"\" oldsrc=\"W020230225502140895131.jpg\" src=\"https://www.chinacdc.cn/jkzt/crb/zl/szkb_11803/jszl_13141/202302/W020230225502140895131.jpg\" width=\"740\"/> </p>\n<p align=\"justify\" style=\"text-align: center;\">　　<span>图<span lang=\"EN-US\">5-3  </span>基于摸底人口数的<span lang=\"EN-US\">60</span>岁以上人群新冠病毒疫苗接种率<span lang=\"EN-US\"><o:p></o:p></span></span> </p>\n<p align=\"justify\" style=\"text-align: center;\">　　<span>（数据来源于<span lang=\"EN-US\">31</span>个省（区、市）及新疆生产建设兵团报告）<span lang=\"EN-US\"><o:p></o:p></span></span> </p>\n<p align=\"justify\">　　注：<span lang=\"EN-US\">1.</span>第一剂次接种率测算中分子为接种目前附条件上市或紧急使用新冠病毒疫苗至少<span lang=\"EN-US\">1</span>剂次的老年人群，分母为<span lang=\"EN-US\">2022</span>年<span lang=\"EN-US\">12</span>月<span lang=\"EN-US\">10</span>日各省上报的老年人摸底登记人口数。<span lang=\"EN-US\">2.</span>全程接种率测算中分子为接种灭活疫苗<span lang=\"EN-US\">2</span>剂次、腺病毒载体疫苗<span lang=\"EN-US\">1</span>剂次、重组蛋白疫苗<span lang=\"EN-US\">3</span>剂次的老年人群，分母为接种灭活疫苗<span lang=\"EN-US\">1</span>剂次、腺病毒载体疫苗<span lang=\"EN-US\">1</span>剂次和重组蛋白疫苗<span lang=\"EN-US\">2</span>剂次的老年人群，并且接种后间隔满<span lang=\"EN-US\">28</span>天（<span lang=\"EN-US\">4</span>周）。<span lang=\"EN-US\">3.</span>第一剂次加强免疫接种率测算分子为完成第一剂次加强免疫接种老年人群，分母为接种灭活疫苗<span lang=\"EN-US\">2</span>剂次、腺病毒载体疫苗<span lang=\"EN-US\">1</span>剂次的老年人群，且全程接种后间隔满<span lang=\"EN-US\">3</span>个月。（由于重组蛋白疫苗实施加强免疫接种的时间短，接种<span lang=\"EN-US\">3</span>剂次重组蛋白疫苗人群目前未包括在分母中）。</p>\n<p align=\"justify\"> </p>\n</div>\n</div>\n</div>"}